Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Financial Results and Performance
ABBV logo

AbbVie Navigates Humira Patent Cliff with 12% Revenue Growth to $15 Billion Driven by Skyrizi and Rinvoq

ABBV10-QFiling Date: 5/8/2026
AbbVie Inc.
Description

What this story covers

AbbVie reports strong Q1 2026 results, with 12% revenue growth driven by Skyrizi and Rinvoq offsetting Humira's decline. The company announced a $100 billion U.S. investment plan and maintained robust shareholder returns through dividends and share repurchases.

Story snapshot

CompanyAbbVie Inc.
TickerABBV
VariantStandard detailed
Duration11:25
Filing type10-Q
PeriodQ1 2026
IndustryHealthcare & Pharmaceuticals
Accession0001551152-26-000017
Sources1

Full Story Script

Content not available for this story.

Primary Sources

sec_filing10-QView on SEC.gov →

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in